This content was published on Oct 24, 2024 On Thursday, the Swiss Federal Railways presented its first fully renovated InterCity tilting train (ICN). Read more: Swiss railways presents first fully ...
Trodelvy shows effectiveness in real-world breast cancer treatment, even after receiving Enhertu therapy. For patients with ...
Yet another therapy with FDA accelerated approval suffers a setback; Sage’s tough year continues; Sanofi drops $326 million ...
Gilead has made the decision to withdraw the accelerated approval of Trodelvy (sacituzumab govitecan) for advanced urothelial cancer in the United States.
The withdrawal of the FDA accelerated approval for locally advanced or metastatic urothelial carcinoma, a type of bladder ...
Gilead is withdrawing the accelerated approval of Trodelvy (sacituzumab govitecan-hziy) for metastatic urothelial cancer.
Gilead, manufacturer of the TROP2-directed antibody-drug conjugate sacituzumab govitecan, made the decision to withdraw the ...
Leerink has upgraded Gilead Sciences (GILD) to outperform, citing the growth outlook for its PrEP medication lenacapavir for ...
Biotech firm Gilead Sciences has announced plans to voluntarily withdraw the US accelerated approval for Trodelvy ...
The other trick is to use olanzapine [Zyprexa]. For some reason, it tends to work very well with breakthrough nausea with ...
Bengaluru: Gilead Sciences said on Friday it was voluntarily withdrawing its drug, Trodelvy, for previously treated patients ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback